Free Newsletter
Sanofi's Lovenox patents 'unenforceable'
Free newsletter via e-mail
Tools
Will the way soon be clear for a generic form of Lovenox? Sanofi-Aventis just lost a bid to save its patents on the anticlotting med, as a U.S. appeals court upheld a lower-court ruling that called the patents unenforceable. That court found that Sanofi failed to disclose certain info on its patent applications--"inequitable conduct" that negated their protection.
The ruling is a win for Teva Pharmaceutical Industries and Amphastar Pharmaceuticals, which originally challenged the patents. They both applied for FDA approval for copycat forms of the med back in 2003. Lovenox's key patent was set to expire in 2012; Sanofi says it's "considering its legal options."
- read the Wall Street Journal news
Related Articles:
Sanofi loses Lovenox patent protection
Lovenox reduces cardio risks but can cause bleeding
Momenta sees delay in generic Lovenox development
Comments
By Anonymous | Posted 10:38am | May 22, 2009
Is there updated info on the status of generic Lovenox?
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
